Amedisys Inc (NASDAQ:AMED) Expected to Post Quarterly Sales of $491.03 Million

Wall Street brokerages expect Amedisys Inc (NASDAQ:AMED) to report sales of $491.03 million for the current quarter, Zacks reports. Six analysts have provided estimates for Amedisys’ earnings. The lowest sales estimate is $487.10 million and the highest is $496.98 million. Amedisys posted sales of $411.60 million during the same quarter last year, which would indicate a positive year over year growth rate of 19.3%. The business is scheduled to issue its next earnings report on Tuesday, July 30th.

On average, analysts expect that Amedisys will report full year sales of $1.97 billion for the current fiscal year, with estimates ranging from $1.94 billion to $1.98 billion. For the next financial year, analysts anticipate that the business will report sales of $2.10 billion, with estimates ranging from $2.04 billion to $2.15 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Amedisys.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.22. The company had revenue of $467.34 million during the quarter, compared to analysts’ expectations of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. Amedisys’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.79 EPS.

AMED has been the subject of a number of analyst reports. ValuEngine raised Zumiez from a “sell” rating to a “hold” rating in a report on Saturday, June 22nd. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 9th. Jefferies Financial Group set a $150.00 price target on Amedisys and gave the stock a “buy” rating in a report on Monday, July 8th. Finally, Raymond James cut RioCan Real Estate Investment Trust to a “hold” rating in a report on Monday, July 15th. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Amedisys presently has a consensus rating of “Buy” and an average price target of $131.74.

NASDAQ AMED traded up $0.19 during trading hours on Friday, reaching $127.75. The company’s stock had a trading volume of 235,264 shares, compared to its average volume of 329,701. The stock has a market capitalization of $4.09 billion, a price-to-earnings ratio of 35.19, a price-to-earnings-growth ratio of 1.59 and a beta of 1.34. Amedisys has a 1-year low of $92.08 and a 1-year high of $140.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91. The firm has a 50-day moving average price of $119.90.

In other news, insider David L. Kemmerly sold 8,125 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $117.77, for a total value of $956,881.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce D. Perkins purchased 2,500 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $111.84 per share, with a total value of $279,600.00. Following the completion of the transaction, the director now directly owns 22,088 shares of the company’s stock, valued at $2,470,321.92. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 45,028 shares of company stock valued at $5,210,707. 2.90% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the company. Alpha Quant Advisors LLC grew its position in shares of Amedisys by 137.0% in the first quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after purchasing an additional 137 shares in the last quarter. Tompkins Financial Corp purchased a new stake in shares of Amedisys in the second quarter valued at approximately $37,000. Captrust Financial Advisors grew its position in shares of Amedisys by 161.8% in the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock valued at $70,000 after purchasing an additional 369 shares in the last quarter. NEXT Financial Group Inc purchased a new stake in shares of Amedisys in the second quarter valued at approximately $82,000. Finally, Meeder Asset Management Inc. grew its position in shares of Amedisys by 102.3% in the first quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock valued at $120,000 after purchasing an additional 488 shares in the last quarter. Institutional investors and hedge funds own 86.45% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: Reverse Stock Split

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.